Compare DexCom, Inc. (DXCM) vs Equinor ASA (EQNR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Equinor ASA — how do they compare? DexCom, Inc. trades at $83.36 (market cap $31.86B), while Equinor ASA trades at $43.29 (market cap $101.62B). The key difference: Equinor ASA is far larger — about 3.2× DexCom, Inc.'s market cap, and Equinor ASA pays a 3.63% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Equinor ASA for 59 Days on average.
| DXCM | EQNR | |
|---|---|---|
Market Cap | $31.86B | $101.62B |
Volume | 3,607,070 | 4,991,782 |
Sector | Health | Energy |
52-Week High | $92.34 | $45.75 |
52-Week Low | $54.84 | $22.41 |
Typical Hold Time | 62 Days | 59 Days |
Enterprise Value | $31.32B | $110.31B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
Equinor (EQNR) trades at $43.415, up 4.34% with strong technical momentum and bullish moving average signals. The stock shows attractive valuation metrics with P/E of 11.63 and EV/EBITDA of 2.39, while maintaining solid profitability with 21.32% ROE. Recent earnings beat expectations in two of the last three quarters, and the company continues shareholder returns through dividends and buybacks.
EQNR presents compelling value with significant upside to the $87.50 consensus price target, though investors face risks from volatile energy prices and declining profit margins. The company's LNG expansion strategy and strong cash flow generation support long-term growth potential, while technical indicators suggest near-term bullish momentum may continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →
